Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

unknown133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_3

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

NCT05908071
completedphase_2

Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

NCT05676073
completedphase_1

A Phase I Study of SHEN26 Capsule in Healthy Participants

NCT05504746

Clinical Trials (3)

Showing 3 of 3 trials
NCT05908071Phase 3

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Unknown
NCT05676073Phase 2

Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Completed
NCT05504746Phase 1

A Phase I Study of SHEN26 Capsule in Healthy Participants

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3